Medivir AB Series B | Ownership
Companies that own Medivir AB Series B
Nordea Investment Management AB
1,946,198
8.01%
-213,392
0.03%
07/31/2018
Max Mitteregger Kapitalförvaltning AB
1,025,000
4.22%
325,000
1.12%
03/29/2018
Danica Pension Livsforsikrings A/S
607,059
2.5%
132,447
0.77%
03/29/2018
Dimensional Fund Advisors LP
351,272
1.45%
-147,220
0%
04/30/2018
Alfred Berg Kapitalförvaltning AB
150,000
0.62%
0
0.02%
07/31/2018
SEB Investment Management AB
89,206
0.37%
-20,776
0%
12/31/2017
Skandia Investment Management AB
55,349
0.23%
0
0%
07/31/2018
Dimensional Fund Advisors Ltd.
34,313
0.14%
7,486
0%
11/30/2017
Naventi Fonder AB
31,357
0.13%
-20,826
0.02%
09/30/2016
Kuylenstierna & Skog SA
20,000
0.08%
0
0.19%
06/30/2017
| Address |
Lunastigen 7
Huddinge AB 141 44
Sweden
|
|
Employees
|
- |
| Website |
http://www.medivir.com |
| Updated |
07/08/2019 |
| Medivir AB engages in the development of pharmaceuticals products. It focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipeline such as remetinostat, birinapant, MV-818, and MIV-711 projects; and partnership pipeline which covers xerclear and MIV-802 project. |
